The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70119 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Lidia Carotenuto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, Department of Neuroscience, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Anticonvulsants, Antipsychotic Agents, Neurons, Epilepsy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Compagnia di San Paolo, Queen Elisabeth Medical Foundation for Neurosciences.
Abstract (Originalsprache)
Background and Purpose Pharmacological activation of neuronal M‐current mediated by Kv7 (Kv7.2–5) potassium channels is a validated mechanism for epilepsy treatment. However, since the market withdrawal of the prototype Kv7 activator retigabine, no Kv7 activator is clinically available for this condition. The object was to identify, characterise and validate new neuronal Kv7 channel activators for epilepsy treatment. Experimental Approach A fluorescence‐based high‐throughput assay was optimised in cells stably expressing Kv7 channels to screen two repurposing libraries including >8000 compounds. Whole‐cell patch clamp, in silico docking, mutagenesis and multielectrode array recordings in human induced‐pluripotent stem cell (hiPSCs)‐derived cortical‐like glutamatergic neurons (iNeurons) were used to evaluate compound(s) potency and efficacy, binding site, and effects on neuronal activity, respectively. Finally, anticonvulsant activity was assessed in two acute seizure models in male mice. Key Results JNJ‐37822681, a fast‐dissociating D 2 receptor antagonist in clinical development as antipsychotic, enhanced Kv7.2–5 currents with potency and efficacy largely comparable to retigabine. In Kv7.2 subunits, JNJ‐37822681 binding site largely overlapped that for retigabine. In iNeurons, JNJ‐37822681 enhanced the M‐current, hyperpolarised the resting membrane potential and reduced spontaneous action potential firing. These effects were blocked by the Kv7 antagonist, XE‐991, and were not reproduced by the D 2 antagonist (‐)‐sulpiride. Finally, JNJ‐37822681 showed anticonvulsant activity in two well‐validated mouse models of acute seizures. Conclusions and Implications Our study reveals that JNJ‐37822681, which lacks retigabine's potential safety issues due to chemical liability and is already confirmed as safe for human use, represents a potential treatment of Kv7‐related neuronal hyperexcitability disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology, Department of Neuroscience, University of Naples Federico II, Naples, Italy.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany.
- Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), Frankfurt am Main, Germany.
- Department of Health Sciences, Research Center FAS@UMG, University of Catanzaro, Catanzaro, Italy.
- Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, Antwerp, Belgium.
- Department of Neurology, University Hospital Antwerp, Antwerp, Belgium.
ORCID-Profile: Maurizio Taglialatela
Förderung
- Ministero dell'Università e della Ricerca
- Compagnia di San Paolo
- Queen Elisabeth Medical Foundation for Neurosciences
- European Joint Programme on Rare Disease JTC 2020
- CUP
- Italian Ministry for University and Research (MUR)
- Italian Ministry of Health (MoH)
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Carotenuto, L., Keminer, O., Carleo, G., Zaliani, A., Leo, A., Citraro, R., De Sarro, G., Dirkx, N., Kaji, M., Weckhuysen, S., Reinshagen, J., Barrese, V., Guida, N., Ostacolo, C., Miceli, F., Gribbon, P., & Taglialatela, M. (2025). The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment. British Journal of Pharmacology. https://doi.org/10.1111/bph.70119
Vancouver
Carotenuto L, Keminer O, Carleo G, Zaliani A, Leo A, Citraro R, et al. The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment. British Journal of Pharmacology. 2025. doi:10.1111/bph.70119
BibTeX
@article{Carotenuto2025,
author = {Carotenuto, Lidia and Keminer, Oliver and Carleo, Giusy and Zaliani, Andrea and Leo, Antonio and Citraro, Rita and De Sarro, Giovambattista and Dirkx, Nina and Kaji, Marcus and Weckhuysen, Sarah and Reinshagen, Jeanette and Barrese, Vincenzo and Guida, Natascia and Ostacolo, Carmine and Miceli, Francesco and Gribbon, Philip and Taglialatela, Maurizio},
title = {The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70119}
}
EUVIMED